China Resources Pharmaceutical Group Ltd (CR Pharma) is an integrated pharmaceutical company. Its business spans manufacturing, distribution, and retail of pharmaceutical and healthcare products. The company offers a portfolio of pharmaceutical products such as chemical drugs (prescription and over-the-counter drugs), biopharmaceutical drugs, and nutritional and healthcare products. These drugs cover major disease areas such as cardiovascular and cerebrovascular diseases, alimentary tract, endocrine disorders, respiratory diseases, orthopaedic conditions, medical nutrition, and gastroenterology. CR Pharma operates its business through three segments – Pharmaceutical Manufacturing, Pharmaceutical Distribution, and Pharmaceutical Retail. The Pharmaceutical Manufacturing segment covers research and development (R&D), production, and sales of pharmaceutical products comprising chemical drugs, traditional Chinese medicine, biological drugs, and supplements. Its product portfolio covers a series of diseases including the cardiovascular system, digestive tract, metabolism, intravenous infusion, paediatrics, and the respiratory system. The company’s Pharmaceutical Distribution segment provides upstream suppliers and downstream customers logistics, marketing, promotion, and other services targeting pharmaceutical products. The Pharmaceutical Retail segment carries out retailing of pharmacy stores.

The company has brands such as 999, Dong-E-E-Jiao, Double Crane, Zizhu, Jiangzhong, and Boya, covering diseases such as cold, gastric conditions, dermatological diseases, pediatric diseases, orthopaedic conditions, and blood diseases.